Resistance mechanisms to SYK inhibition in acute myeloid leukemia

Spleen tyrosine kinase (SYK) is a non-mutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of resistance to single agent treatment in vivo. We con...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Discov
Main Authors: Cremer, Anjali, Ellegast, Jana M., Alexe, Gabriela, Frank, Elizabeth S., Ross, Linda, Chu, S. Haihua, Pikman, Yana, Robichaud, Amanda, Goodale, Amy, Häupl, Björn, Mohr, Sebastian, Rao, Arati V., Walker, Alison R., Blachly, James S., Piccioni, Federica, Armstrong, Scott A., Byrd, John C., Oellerich, Thomas, Stegmaier, Kimberly
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058374/
https://ncbi.nlm.nih.gov/pubmed/31771968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0209
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items